相关实验视频
Updated: Jul 19, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
开发用于退行性神经疾病前症状阶段的药物:挑战和机遇
1Human Medicines, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, Netherlands.
Revue neurologique
|August 9, 2023
概括
在症状出现之前预防神经退行性疾病至关重要. 本文探讨了这些疾病的前症状治疗策略的机遇和挑战.
科学领域:
- 神经学 神经学
- 预防医学 预防医学
- 生物标志物研究 生物标志物研究
背景情况:
- 神经退行性疾病因预期寿命延长而越来越普遍.
- 这些疾病往往在临床症状出现前几年就开始.
- 这一症状前阶段为早期干预提供了一个窗口.
研究的目的:
- 提供关于神经退行性疾病症状前预防的机会和挑战的观点.
- 检查有效的症状前治疗策略的要求.
- 讨论治疗无症状个体的伦理考虑.
主要方法:
- 关于神经退行性疾病进展的当前文献的综述.
- 分析症状前干预的可能性.
- 讨论生物标志物开发和验证需求.
主要成果:
- 识别症状前窗口是有效干预的关键.
- 生物标志物对于选择参与者和测量治疗效果至关重要.
- 在症状前的试验中,平衡好处,风险和不确定性至关重要.
结论:
- 神经退行性疾病的症状前预防提供了显著的机会.
- 克服挑战需要强大的生物标志物和仔细的伦理考虑.
- 早期干预策略有望改善患者的治疗结果.
相关概念视频
Parkinson's Disease: Overview
598
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
598
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
Microorganisms in Medicine and Therapeutics
54
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
54
Parkinson's Disease: Treatment
299
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
299

